Notes

Why ADHD Medication And Pregnancy Is Fast Becoming The Hottest Trend Of 2024
ADHD Medication and Pregnancy

Physicians often struggle to counsel patients about the security of their ADHD medication during pregnancy. In the absence research, doctors must weigh the advantages and risks of using medications during pregnancy.

A study of a population-based sample has followed 898 babies who were born to mothers who had taken ADHD medications during pregnancy (stimulants amphetamine methylphenidate dexamphetamine ; non-stimulants modafinil atomoxetine clonidine), until they were identified as having a developmental disorder, died, or left the country.

Risk/Benefit Discussion

CAP Smart Take:

Doctors are concerned with the long-term effects exposure to drugs during pregnancy can result in, especially for centrally stimulating medications such as those used to treat ADHD. It is crucial that women receive proper counseling from their physicians about the risk/benefit of using medication prior to conception and throughout pregnancy. In this CAP smart approach, we review the most recent research on this topic and how they might influence the practice of a physician.

Animal studies and illicit drug research suggests that stimulant medication passes to the fetus via the placenta, and may negatively impact fetal growth and development. However, there are limited data on the response of the fetus to the therapeutic doses of prescription stimulant medications during pregnancy, and most of this evidence comes from single-arm case-control studies that are not sufficiently powered to detect possible significant connections.


The most recent study by Cohen et al4 is distinct from other studies, as it is the biggest and most carefully controlled. The study included a sample of 364,012 pregnant women from the Danish Medical Registry, and information on medication use was gathered by analyzing prescriptions that were redeemed. Researchers excluded women who had taken SSRIs or clonidine because these drugs can interfere with fetal NMDA and increase the risk of developing neurodevelopmental disorders, such as autism and ADHD. The authors adjusted their analyses to take into account the timing of exposure and to control for confounding factors.

The results of this study and other limited trials indicate that the vast number of women who continue using their stimulant medications prescribed for ADHD during pregnancy are not experiencing adverse effects on their fetuses. As a result, it is likely that a lot of women will continue to use their medication for ADHD during pregnancy. It is important for doctors to consider the benefits and risks of these medications prior to giving their pregnant patients the advice to stop taking these medications. Whatever decision they make, it is essential that pregnant women with ADHD educate their spouses or partners, extended family members as well as their employers about the choice they've made. This is because the symptoms of hyperactivity, inattention, and impulsivity are likely to come back after the mother ceases taking her medications.

Pregnancy Tests

Preconception counseling for women suffering from ADHD who wish to become pregnant should focus on a comprehensive treatment plan that incorporates both pharmacologic and behavioral treatments and continuous monitoring throughout the period of perinatal care. The plan should include a discussion of current medication regimens, especially in the first trimester where dangers to the baby resulting from untreated ADHD are greatest. This should be a joint effort between primary care and psychiatry and Obstetrics.

The risk/benefit discussion should also consider how a woman will plan to manage her symptoms of ADHD during pregnancy, as well as the effects on family functioning and what she might feel about discontinuing psychostimulant therapy during the initial stages of pregnancy. This should be based on an exhaustive review of the available evidence and be mindful of the individual needs of the patient and concerns.

The authors of a huge study that examined children who were exposed to ADHD medications during utero concluded that "continuation psychostimulant use during the early stages of pregnancy was not associated with adverse birth outcomes and, if anything, it was associated with less stress among mothers." However the conclusion they reached is not without a few limitations. The study did take into consideration other factors such as the duration of time stimulant medication was used as well as the dose and sociodemographics. Additionally, there isn't any controlled study that examines the safety of continuing psychostimulant use among nursing mothers.

There isn't a clear evidence from a scientific study regarding the safety of ADHD medication during pregnancy. However, most doctors have a general knowledge of the research findings and apply best practices when assessing each patient's specific needs. For example, it is well-known that there is a higher rate of cardiac malformations in infants born to mothers who took methylphenidate in the first trimester of pregnancy (Cooper et al., 2018) It is important to remember that this finding was based on a single study and did not account for variations in the demographics of patients or underlying psychiatric co-morbidity.

In a recent survey ADDitude readers said that they were more likely to quit their ADHD medication during early pregnancy than in previous. Women who stopped taking psychostimulants in the first trimester noticed an increase in depression symptoms. They also reported that they were less able to enjoy their pregnancy and rated their families functioning as more difficult than those who continued or increased their dosages of ADHD medication.

Work Functioning Test

The work function test is a crucial aspect of the test to determine if an individual is able to carry out their job. The test is designed to evaluate functional limitations. It includes graded material handling (lifting to different heights pulling and pushing) and positional tolerance exercises (sitting in a chair, standing, balancing, walking or stooping, kneeling, crawling) and other relevant tests for specialized testing (hand manipulation). The evaluator will analyze the results and come up with a return to work conclusion. ROC curves are used to determine the point at which there is a minimum misclassification (MIC) for both the general and physical working ability as well as the functional problem score.

The MIC is calculated according to the COnsensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) checklist. This method separates scores for general and physical work capabilities and work-functioning issues, by answering an anchor question. This prevents any change in metrics from affecting the average.

Driving Test

The gold standard for treating ADHD is psychostimulant medications. It helps reduce symptoms and improves functioning in other domains, notably driving safety. Impairment due to severe untreated ADHD can have serious financial and psychosocial effects.

Psychotherapeutic interventions like cognitive behavioral therapy (CBT) and "coaching" strategies have also been proven to reduce symptoms and improve functioning. These strategies could aid women in adjusting their routines and use their coping skills to minimize the effects of their ADHD on their work and other areas.

All of these factors are important to consider when deciding whether or not to pursue psychostimulant therapy. As the most recent data available show, while there is some concern regarding the effects of pregnancy on outcomes after in-utero exposure to stimulant medication, the relative risks are small and the results are affected by other medications, maternal health care utilization as well as physical and mental health and other comorbidities. Bang Madsen K, Bliddal M, Skoglund CB, Larsson H, Munk-Olsen, Hove Thomsen P, Bergink V. In visit my web site to attention deficit hyperactivity disorder medication and long-term effects on offspring.

Website: https://www.iampsychiatry.com/adult-adhd-medication